Alyeska Investment Group, L.P. Cerevel Therapeutics Holdings, Inc. Transaction History

Alyeska Investment Group, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $2.24 Million - $3.64 Million	87,782 New	87,782 $2.48 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $2.17 Million - $3.9 Million	-105,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $7.51 Million - $11.3 Million	-319,767 Reduced 75.28%	105,000 $3.68 Million
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $8.5 Million - $15.5 Million	-399,622 Reduced 48.47%	424,767 $12.5 Million
Q2 2021 Aug 16, 2021	SELL	$12.56 - $29.69 $2.36 Million - $5.58 Million	-188,091 Reduced 18.58%	824,389 $21.1 Million
Q1 2021 May 17, 2021	SELL	$12.37 - $17.74 $4.07 Million - $5.84 Million	-329,005 Reduced 24.53%	1,012,480 $13.9 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $13.2 Million - $24.5 Million	1,341,485 New	1,341,485 $22.2 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.